Pfizer Inc/BioNTech SE vaccine in preventing infection by the coronavirus dropped to 47% from 88% six months after the second dose, according to data published on Monday that U.S.
health agencies considered when deciding on the need for booster shots.The data, which was published in the Lancet medical journal, had been previously released in August ahead of peer review.